1142 related articles for article (PubMed ID: 32928094)
61. Recent advances in mesoporous silica nanoparticle-based targeted drug-delivery systems for cancer therapy.
Li Y; Deng G; Hu X; Li C; Wang X; Zhu Q; Zheng K; Xiong W; Wu H
Nanomedicine (Lond); 2022 Aug; 17(18):1253-1279. PubMed ID: 36250937
[TBL] [Abstract][Full Text] [Related]
62. Dual response to pH and chiral microenvironments for the release of a flurbiprofen-loaded chiral self-assembled mesoporous silica drug delivery system.
Wu L; Gou K; Guo X; Guo Y; Chen M; Hou J; Li S; Li H
Colloids Surf B Biointerfaces; 2021 Mar; 199():111501. PubMed ID: 33338882
[TBL] [Abstract][Full Text] [Related]
63. Controllable synthesis of versatile mesoporous organosilica nanoparticles as precision cancer theranostics.
Cheng Y; Jiao X; Fan W; Yang Z; Wen Y; Chen X
Biomaterials; 2020 Oct; 256():120191. PubMed ID: 32593907
[TBL] [Abstract][Full Text] [Related]
64. Fabrication of Chitosan-coated Mesoporous Silica Nanoparticles Bearing Rosuvastatin as a Drug Delivery System.
Ghahfarokhi MR; Dini G; Movahedi B
Curr Drug Deliv; 2022; 19(1):64-73. PubMed ID: 34151762
[TBL] [Abstract][Full Text] [Related]
65. Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors.
van Rijt SH; Bölükbas DA; Argyo C; Datz S; Lindner M; Eickelberg O; Königshoff M; Bein T; Meiners S
ACS Nano; 2015 Mar; 9(3):2377-89. PubMed ID: 25703655
[TBL] [Abstract][Full Text] [Related]
66. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications.
Lee JE; Lee N; Kim T; Kim J; Hyeon T
Acc Chem Res; 2011 Oct; 44(10):893-902. PubMed ID: 21848274
[TBL] [Abstract][Full Text] [Related]
67. Mesoporous silica nanoparticles in drug delivery and biomedical applications.
Wang Y; Zhao Q; Han N; Bai L; Li J; Liu J; Che E; Hu L; Zhang Q; Jiang T; Wang S
Nanomedicine; 2015 Feb; 11(2):313-27. PubMed ID: 25461284
[TBL] [Abstract][Full Text] [Related]
68. Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method.
Yang G; Li Z; Wu F; Chen M; Wang R; Zhu H; Li Q; Yuan Y
Int J Nanomedicine; 2020; 15():1661-1675. PubMed ID: 32210559
[TBL] [Abstract][Full Text] [Related]
69. Mesoporous silica nanoparticles: a smart nanosystem for management of breast cancer.
Poonia N; Lather V; Pandita D
Drug Discov Today; 2018 Feb; 23(2):315-332. PubMed ID: 29128658
[TBL] [Abstract][Full Text] [Related]
70. Hybrid mesoporous silica nanospheres modified by poly (NIPAM-co-AA) for drug delivery.
Zhang K; Zhou D; Wang Z; Zhang Y; He P
Nanotechnology; 2019 Aug; 30(35):355604. PubMed ID: 31071691
[TBL] [Abstract][Full Text] [Related]
71. Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice.
Wagner J; Gößl D; Ustyanovska N; Xiong M; Hauser D; Zhuzhgova O; Hočevar S; Taskoparan B; Poller L; Datz S; Engelke H; Daali Y; Bein T; Bourquin C
ACS Nano; 2021 Mar; 15(3):4450-4466. PubMed ID: 33648336
[TBL] [Abstract][Full Text] [Related]
72. Simultaneous Single-Particle Tracking and Dynamic pH Sensing Reveal Lysosome-Targetable Mesoporous Silica Nanoparticle Pathways.
Zhang RL; Pratiwi FW; Chen BC; Chen P; Wu SH; Mou CY
ACS Appl Mater Interfaces; 2020 Sep; 12(38):42472-42484. PubMed ID: 32657564
[TBL] [Abstract][Full Text] [Related]
73. Fluorescent carbon dot modified mesoporous silica nanocarriers for redox-responsive controlled drug delivery and bioimaging.
Jiao J; Liu C; Li X; Liu J; Di D; Zhang Y; Zhao Q; Wang S
J Colloid Interface Sci; 2016 Dec; 483():343-352. PubMed ID: 27569517
[TBL] [Abstract][Full Text] [Related]
74. Mesoporous silica nanoparticle-supported nanocarriers with enhanced drug loading, encapsulation stability, and targeting efficiency.
Oh JY; Yang G; Choi E; Ryu JH
Biomater Sci; 2022 Mar; 10(6):1448-1455. PubMed ID: 35229845
[TBL] [Abstract][Full Text] [Related]
75. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
[TBL] [Abstract][Full Text] [Related]
76. Amino-decorated mesoporous silica nanoparticles for controlled sofosbuvir delivery.
Mehmood Y; Khan IU; Shahzad Y; Khan RU; Khalid SH; Yousaf AM; Hussain T; Asghar S; Khalid I; Asif M; Shah SU
Eur J Pharm Sci; 2020 Feb; 143():105184. PubMed ID: 31846695
[TBL] [Abstract][Full Text] [Related]
77. Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery.
Yu L; Chen Y; Lin H; Du W; Chen H; Shi J
Biomaterials; 2018 Apr; 161():292-305. PubMed ID: 29427925
[TBL] [Abstract][Full Text] [Related]
78. Dual-Therapeutics-Loaded Mesoporous Silica Nanoparticles Applied for Breast Tumor Therapy.
Li X; He G; Jin H; Tao J; Li X; Zhai C; Luo Y; Liu X
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46497-46503. PubMed ID: 31738505
[TBL] [Abstract][Full Text] [Related]
79. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery.
Baeza A; Colilla M; Vallet-Regí M
Expert Opin Drug Deliv; 2015 Feb; 12(2):319-37. PubMed ID: 25421898
[TBL] [Abstract][Full Text] [Related]
80. Strategies to Regulate the Degradation and Clearance of Mesoporous Silica Nanoparticles: A Review.
Zhang Y; Lin X; Chen X; Fang W; Yu K; Gu W; Wei Y; Zheng H; Piao J; Li F
Int J Nanomedicine; 2024; 19():5859-5878. PubMed ID: 38887691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
